Radiographic partial response (PR) or sustained stable disease (SD) was observed in 5 patients treated with trametinib monotherapy among which, 4 had neurofibromatosis type 1; one patient with NF1 mutant sporadic glioma had SD followed by disease progression (Supplementary Table S4). Here, NF1 is linked to central nervous system cancer.